News

Under the partnership, Ultragenyx will receive an exclusive license to one preclinical Takeda candidate in an unspecified predetermined area of use. Ultragenyx will retain an exclusive option to

Sirukumab is being co-developed by GlaxoSmithKline (GSK) and Janssen Biologics in a partnership that startesd in December 2011. It is a human monoclonal IgG kappa antibody that binds

"The preclinical data we presented at ASH in December 2015 supported the evaluation of M281 as a strategy for the rapid and reversible suppression of pathogenic autoantibodies or

The Committees recommended the inclusion of abuse-deterrent labeling for intranasal (11 to 4) and intravenous (9 to 6) routes of abuse. They voted against inclusion of abuse-deterrent labeling

Each unit consists of (i) one share of Pieris’ common stock or non-voting series A convertible preferred stock convertible into one share of common stock, (ii) 0.40 warrants

Over three years, Adimab will use its proprietary, yeast-based discovery platform to generate IgGs or bispecifics for development as therapeutic products for multiple targets chosen by Innovent. Innovent

Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer. Dr. Steve Quay, President

The collaboration will help support multiple Phase 1 and 2 clinical trials testing Opdivo as monotherapy, in combination with Yervoy, or in regimens with other agents, radiation or

The double-blind, placebo-controlled study randomized 153 patients into four treatment arms. All participants were on statin therapy and had LDL-C levels between 70 and 190 mg/dL. At baseline,